Tecentriq-Chemo Combo Under FDA Review as First-line Therapy for PD-L1-positive, Metastatic Triple-negative Breast Cancer

Tecentriq-Chemo Combo Under FDA Review as First-line Therapy for PD-L1-positive, Metastatic Triple-negative Breast Cancer
The U.S. Food and Drug Administration (FDA) is reviewing Genentech’s request for Tecentriq (atezolizumab) to be approved, in combination with the chemotherapy Abraxane (nab-paclitaxel), as a first-line treatment for certain triple-negative breast cancer patients. The supplemental Biologics License Application (sBLA), which covers surgery-ineligible patients with locally advanced or metastatic triple negative breast cancers (TNBCs) that produce the PD-L1 factor, was priority review status. A decision is expected by March 12. “Tecentriq in combination with nab-paclitaxel [Abraxane] has the potential to meaningfully advance treatment for people with PD-L1-positive, metastatic triple-negative breast cancer. People need more options for this type of breast cancer, which is particularly difficult to treat,” Sandra Horning, MD, chief medical officer and head of Global Product Development, said in a press release. If approved, the combination will be the first cancer immunotherapy for PD-L1-positive, metastatic TNBC. Tecentriq, developed by Genentech, is an antibody that selectively targets PD-L1, a protein produced by cancer
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.